Investment
Features
FeesSafety
Academy
More
Pluang+

Compare KraneShares CSI China Internet ETF (KWEB) vs 10X Genomics Inc (TXG) Price & Performance

KraneShares CSI China Internet ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

KraneShares CSI China Internet ETF vs 10X Genomics Inc — how do they compare? KraneShares CSI China Internet ETF trades at $27.78, while 10X Genomics Inc trades at $58.54 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.

KWEBTXG
Sector
Sector/ThematicHealth
52-Week High
$42.94$58.57
52-Week Low
$23.63$11.34
Market Cap
$7.64B
Enterprise Value
$7.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

KraneShares CSI China Internet ETF

KWEB, the KraneShares CSI China Internet ETF, trades at $28.66, up 0.99% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights institutional buying, China's export growth, and AI-driven factory rebounds, though RSI levels suggest potential overbought conditions. The ETF provides exposure to Chinese internet and AI companies, with performance influenced by economic policies and tech sector developments.

The outlook for KWEB is cautiously optimistic, driven by AI expansion and government support, but risks include U.S.-China tensions and regulatory shifts. Investors may find value in its tech concentration, yet must weigh geopolitical and market volatility. Analyst sentiment is mixed, balancing growth potential against structural risks.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

About KraneShares CSI China Internet ETF

KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.

Read more on KWEB

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG